Pillar 1 - FTO (new thread), page-1641

For those interested, there are now 26 different cancer types that have been linked to FTO overexpression.

Here is the link: https://assets.researchsquare.com/files/rs-983314/v1/09f8aafb-8360-4f60-97ae-e7526cb3372c.pdf?c=1634843062

The new discovery has been made in Osteosarcoma, a type of bone cancer. What I found particularly interesting has been shared as a screenshot below. Simply put, the researchers collected 42 real patient osteosarcoma samples and found that 64.3% of them were overexpressing FTO.



Here is a list of all the known cancer types linked to FTO overexpression.



By comparison, as of March 2020, Keytruda was approved for use in 15 different cancer types. There are almost twice as many cancer types that have been linked to FTO overexpression as there are cancer types approved for Keytruda.




I firmly believe that we are currently first-in-class and best-in-class for the next generation of anti-cancer therapies, targeting specifically the m6A mRNA machinery. If indeed FTO is a targetable protein for anti-cancer therapy, I also believe that RAC is one of the largest opportunities on the ASX.

How many more cancer types will be linked to FTO overexpression as the weeks and months roll on?